AbbVie SG&A Expenses 2012-2026 | ABBV

AbbVie sg&a expenses for the twelve months ending March 31, 2026 were $14.295B, a 2.95% decline year-over-year.

  • AbbVie annual sg&a expenses for 2025 were $14.01B, a 5.03% decline from 2024.
  • AbbVie annual sg&a expenses for 2024 were $14.752B, a 14.61% increase from 2023.
  • AbbVie annual sg&a expenses for 2023 were $12.872B, a 15.65% decline from 2022.

AbbVie SG&A Expenses 2012-2026 | ABBV

  • AbbVie annual sg&a expenses for 2025 were $14.01B, a 5.03% decline from 2024.
  • AbbVie annual sg&a expenses for 2024 were $14.752B, a 14.61% increase from 2023.
  • AbbVie annual sg&a expenses for 2023 were $12.872B, a 15.65% decline from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B